MedicaidPrior AuthLow impact
Fyarro (sirolimus protein-bound particles for injectable suspension) (Revised)
Humana·LA · Oncology, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Fyarro (sirolimus protein-bound particles for injectable suspension), an mTOR inhibitor used to treat locally advanced unresectable or metastatic perivascular epithelioid cell tumors (PEComa). The policy requires prior authorization for this specialty oncology drug with specific clinical criteria including confirmed diagnosis and monotherapy administration.
Action Required
Before January 1, 2026: Billing team must update prior authorization tracking system to flag Fyarro (sirolimus protein-bound particles for injectable suspension) for Louisiana Medicaid patients with perivascular epithelioid cell tumor. Providers must obtain prior authorization by documenting locally advanced unresectable or metastatic PEComa diagnosis and confirming monotherapy use. Visit www.humana.com/PAL for medical coding information and submission requirements.